Harmony Biosciences (HRMY) Set to Announce Quarterly Earnings on Wednesday

Harmony Biosciences (NASDAQ:HRMY) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of $1.10 per share and revenue of $274.04 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.32. The company had revenue of $261.28 million during the quarter, compared to the consensus estimate of $250.77 million. During the same period last year, the firm posted $0.92 earnings per share. The company’s revenue for the quarter was up 30.3% on a year-over-year basis. On average, analysts expect Harmony Biosciences to post $3.79 EPS for the current fiscal year and $4.06 EPS for the next fiscal year.

Harmony Biosciences Trading Up 3.0%

Shares of NASDAQ HRMY opened at $37.95 on Wednesday. The firm’s 50-day moving average price is $39.78 and its 200-day moving average price is $34.72. Harmony Biosciences has a 1-year low of $25.90 and a 1-year high of $43.49.

Insider Buying and Selling

In related news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $43.05, for a total value of $1,543,428.60. Following the sale, the insider directly owned 13,115 shares of the company’s stock, valued at $564,600.75. This trade represents a 73.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 72,406 shares of company stock worth $3,108,520. Corporate insiders own 11.00% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on HRMY shares. Mizuho upped their target price on shares of Harmony Biosciences from $50.00 to $51.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. UBS Group reissued a “neutral” rating and issued a $37.00 target price on shares of Harmony Biosciences in a research report on Wednesday, August 5th. LADENBURG THALM/SH SH assumed coverage on shares of Harmony Biosciences in a research note on Thursday, October 15th. They issued a “buy” rating and a $55.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $50.00 price objective on shares of Harmony Biosciences in a report on Monday, October 19th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Harmony Biosciences in a research note on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Harmony Biosciences presently has an average rating of “Moderate Buy” and an average price target of $48.20.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.